Welcome to our dedicated page for Metsera SEC filings (Ticker: MTSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Metsera, Inc. (MTSR) SEC filings page provides access to the company’s regulatory history as a former Nasdaq-listed biotechnology issuer and documents its transition into a wholly owned subsidiary of Pfizer Inc. Metsera’s filings include multiple Forms 8-K detailing material events such as the signing and later amendment of the Agreement and Plan of Merger with Pfizer, the terms of unsolicited proposals from Novo Nordisk A/S, and the announcement of positive Phase 2b data for MET-097i, a fully biased, ultra-long acting GLP-1 receptor agonist with potential for monthly dosing in obesity.
Key filings for MTSR users include the September 21, 2025 and November 7, 2025 Forms 8-K describing the original and amended Pfizer merger agreements, including cash consideration and non-transferable contingent value rights (CVRs) tied to clinical and regulatory milestones for MET-097i and the MET-233i/MET-097i combination product. The November 13, 2025 Form 8-K reports completion of the merger, conversion of Metsera shares into cash plus CVRs, the resulting change in control, and the steps taken to delist MTSR from the Nasdaq Global Select Market and to deregister the common stock.
Additional 8-Ks capture Metsera’s responses to litigation initiated by Pfizer, the Board’s determinations that certain Novo Nordisk proposals constituted “Superior Company Proposals,” and detailed descriptions of proposed transaction structures, interim funding, non-voting convertible preferred stock, and alternative CVR terms. Other filings, such as the September 29, 2025 Form 8-K, furnish clinical data summaries for the VESPER-1 and VESPER-3 trials of MET-097i and outline the broader pipeline, including MET-233/097, MET-034/097, MET-097o, and MET-815.
On Stock Titan, these filings can be paired with AI-powered summaries that explain complex merger provisions, CVR mechanics, and clinical trial disclosures in plain language. Users can quickly see how each filing affected Metsera’s corporate status, from the initial merger announcement through shareholder approval, closing, and delisting. While MTSR no longer trades, its SEC filings remain a valuable resource for understanding the company’s development programs, transaction terms, and the regulatory steps associated with its acquisition by Pfizer.